(0-78)%, 3 .37 (0-69)%, 4 -09 (0-91)%, 4.34 (1-60)%, and 3 49 (0-98)%, respectively, expressed as a percentage of the nominal dose. The Nebuhaler and Bricanyl Spacer spacer devices were found to increase the relative bioavailability of salbutamol to the lung compared with the MDI alone. Compared with the MDI the inhalation aid increases were much greater than the intra-individual variability of the urinary excretion method. In 11 individuals who each repeated the same inhalation procedure on four separate occasions, the mean (SD) coefficient of variation was [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] (2-36)%. The mean (SD) 24 hour urinary excretion of salbutamol and its metabolites was 26-6 (6 79), 27'0 (7 95) , and 55-6 (9- Inhalation from a static aerosol cloud, from within these devices, reduces particle velocity during inspiration thereby limiting oropharyngeal impaction and systemic absorption. These spacers also overcome the problems of poor coordination and enable an increase in the proportion of the dose delivered to the therapeutically active sites within the lungs.89
We have shown that the percentage (amount) of an inhaled dose of salbutamol recovered in a urine sample taken 30 minutes after inhalation is an index of the relative amounts of drug deposited in the respiratory tract -that is, the relative bioavailability of salbutamol to the lung. ' On each occasion subjects exhaled to residual volume before a slow deep inhalation over a period of 5-10 seconds, followed by a 10 second breath hold."I This manoeuvre was repeated four times (4 x 100 jg doses from the MDI) with an interval of 30 seconds between each dose. Each method was assessed on a separate day, with seven day washout intervals, and the order of administration was randomised.
Subjects emptied their bladders immediately before the doses and then urine samples were collected at 30 minutes and subsequently pooled until 24 hours after the dose. The volume of urine passed was recorded and pH measured. Urine samples were stored at -20°C before analysis. A previously validated sensitive high performance liquid chromatography (HPLC) method was used to measure urine concentrations of salbutamol and its metabolite, the sulphate ester conjugate.'0 Immediately after inhalation of the four doses each spacer was washed with 6 ml methanol followed by distilled water. These washings were collected and made up to 100 ml in a volumetric flask and measured by the same method as the urine samples.
The intrasubject reproducibility of the urinary method was assessed in 11 healthy volunteers (eight from the above group). Following inhalation of 4 x 100 gg salbutamol doses from a Ventolin MDI using a standardised inhaler technique'' urine samples were provided at 0-30 minutes and 0 5-24 hours after the dose. Urine samples were analysed as above. Each individual repeated this procedure on three other occasions (four in total) with suitable washout periods in between. From the four sets of results for each individual the average amount excreted in the urine was calculated, together with the coefficient of variation. From these individual average values and coefficients of variation the mean (SD) for the 11 subjects was calculated for the 0-30 minute and 0-24 hour samples.
DATA ANALYSIS
Statistical comparisons were made using the Wilcoxon signed rank test together with the median difference and 95% confidence intervals.
Results
Ten healthy subjects (five women) with mean (SD) age, weight, and height of 29-3 (7 3) years, 68 3 (10 7) kg, and 1 71 (0 12) m, respectively, completed the spacer study. Their mean (SD) FEVy was 103 4 (9 3)% of the predicted value. The pH of all urine samples was between 4-5 and 6-5.
An increase in the urinary salbutamol excretion 30 minutes after dosing was seen when the MDI was used with the aid of a Volumatic, Nebuhaler, and Bricanyl Spacer, and with the open mouth method (table 1, figure). Newman et al,9 and 54 7% of the dose was left in the Volumatic, which is slightly larger than 44-8% and 37-9% following inhalation by volunteers and asthmatics, respectively, reported in a study using salbutamol labelled with technetium-99m."3
The Nebuhaler was found to be the most efficient inhalation aid of those evaluated, despite using a Ventolin MDI canister instead of the Bricanyl MDI (Astra Pharmaceuticals) for which it is designed. There was a significant group.bmj.com on April 3, 2017 -Published by http://thorax.bmj.com/ Downloaded from (p < 0 05) increase in the relative bioavailability of salbutamol in the lung when the Nebuhaler was used with the Ventolin MDI compared with the MDI alone. The 30 minute urinary excretion (corresponding to the relative lung bioavailability) of salbutamol following Ventolin MDI use with the Nebuhaler was 28 8% higher than that of the Volumatic, but the differences did not reach statistical significance because of the low numbers. This improvement may result from a favoured alteration of the aerosol cloud from the Ventolin MDI by the Nebuhaler spray nozzle, or from the more aerodynamic shape of the Nebuhaler. The volunteers who used these inhalation devices were extensively trained with the inhalation technique. In practice, therefore, when the inhalation technique is suboptimal the improved delivery to the lung from these devices should be greater.
Vidgren et al,8 using gamma scintigraphy with technetium-99m labelled disodium cromoglycate, reported that the mean fractional lung deposition increased by 56% following inhalation with a Nebuhaler compared with the MDI. This value is similar to the 53 4% increase from this study. Greater lung deposition was also reported by Newman et al9 using gamma scintigraphy with technetium-99m labelled Teflon. This study revealed a 140% increase in the pulmonary deposition with the Nebuhaler compared with the MDI. A recent report'3 using salbutamol labelled with technetium-99m formulated in an MDI"4 has shown greater peripheral lung deposition when using a Volumatic with the MDI. In normal and asthmatic subjects the peripheral lung deposition was reported to be 12-02% and 26-97%, respectively, greater using the Volumatic than the MDI on its own. The greater deposition in the volunteers could reflect their inhalationtechnique because the training given would have been recent. The values are similar to the 19-1% increase we have demonstrated for the Volumatic.
Similar relative bioavailabilities to the lung (3 49% and 4 09%) were observed after inhalation with the open mouth technique and with the Bricanyl Spacer. Vidgren et all reported a 75% greater pulmonary deposition from the Bricanyl Spacer than with the MDI, which is higher than the 44 5% obtained from this study. They also reported a total systemic availability of 56% for the Bricanyl Spacer which is also higher than the 43-8% from this study. The pulmonary deposition from the Bricanyl Spacer was not as great as that using the large volume inhalers and more was swallowed. This finding is as expected because the Bricanyl Spacer is a tube extension spacer (80 ml) and its design affects the deposition pattern of the inhaled dose compared with the large volume spacers. The open mouth method is analogous to the tube spacer because the increased distance between the mouth and the actuator is the same. The reduced aerosol velocity of both these methods allows a time lag between actuation and inspiration. The Bricanyl Spacer provides a control for the direction of the aerosol, thus preventing accidental misdirection of the spray cloud (for example, into the eyes) which may occur with the open mouth method.
The increased lung deposition when MDIs are used with large volume spacer devices, especially in those with poor inhalation technique, should improve lung function. However, previous studies have reported conflicting clinical efficacy of large volume spacers.9'"7 These studies were not dose ranging and did not include an assessment of each subject's inhalation technique. Although volunteers were used in this study it can be concluded that, if similar amounts of drug are deposited into the airways of the lungs, an equivalent lung function response should be obtainedbioequivalence of inhaled products.'8 The results when the spacers were used, however, showed that the amount deposited in the lungs increased and, therefore, the clinical significance of increased lung deposition should be investigated. Using the urinary salbutamol method it is now possible to carry out clinical studies using the patients' own inhaled products and spacers to correlate improved lung bioavailability, decreased systemic availability, and pharmacodynamic outcome (efficacy and safety), together with an identification of the inhaler technique to be used and the dose required. If the outcome of these is positive, then the approach advocated by Keeley7 for the universal use of spacers could be adopted, rather than recommendations being restricted to children, '9 
